Search bioRxiv⌕ Search

Biology subjects

Fair, M.

Publications and source records attributed to Fair, M..

2 recordsLinked to original sources

Retinol Binding Protein 4 reactivates latent HIV-1 via the JAK/STAT5 and JNK pathways

Reactivation of the latent viral reservoirs is crucial for a cure of HIV/AIDS. However, current latency reversing agents are inefficient and the endogenous factors that have the potential to reactivate HIV in vivo remain poorly understood. To identify natural activators of latent HIV-1, we screened a comprehensive peptide/protein library derived from human hemofiltrate, representing the entire blood peptidome, using J-Lat cell lines harboring transcriptionally silent HIV-1 GFP reporter viruses. Fractions potently reactivating HIV-1 from latency contained human Retinol Binding Protein 4 (RBP4), the carrier of retinol (vitamin A). We found that retinol-bound holo-RBP4 but not retinol-free apo-RBP4 strongly reactivates HIV-1 in a variety of latently infected T cell lines. Functional analysis revealed that this reactivation depends on the JAK/STAT5 and JNK pathways but does not require retinoic acid production. High levels of RBP4 were detected in plasma from both healthy individuals and people living with HIV-1. Physiological concentrations of RBP4 induced significant viral reactivation in latently infected cells from individuals on long-term antiretroviral therapy with undetectable viral loads. As a potent natural HIV-1 latency-reversing agent, RBP4 offers a novel approach to activating the latent reservoirs and bringing us closer to a cure.

immunology↗

Cloning and functional characterization of novel human neutralizing anti-interferon-alpha and anti-interferon-beta antibodies

Type I interferons (IFNs) play a pivotal role in immune response modulation, yet dysregulation is implicated in various disorders. Therefore, it is crucial to develop tools that facilitate the understanding of their mechanism of action and enable the development of more effective anti-IFN therapeutic strategies. In this study, we isolated, cloned, and characterized anti-IFN- and anti-IFN-{beta} antibodies (Abs) from peripheral blood mononuclear cells of individuals treated with IFN- or IFN-{beta}, harboring confirmed neutralizing Abs. Clones AH07856 and AH07857 were identified as neutralizing anti-IFN--specific with inhibition against IFN-2a, -2b, and -K subtypes. Clones AH07859 and AH07866 were identified as neutralizing anti-IFN-{beta}1a-specific signaling, and able to block Lipopolysaccharide or S100 calcium binding protein A14-induced IFN-{beta} signaling effects. Cloned Abs bind rhesus but not murine IFNs. The specificity of inhibition between IFN- and IFN-{beta} suggests potential for diverse research and clinical applications.

immunology↗